Jan 24-25, 2018

San Francisco, CA

Day One
Wednesday January 25th, 2017

Day Two
Thursday January 26th, 2017

Registration & Coffee

Chair’s Opening Remarks

  • Francis Lee Independent Immunopharmacology Consultant - , Formerly Senior Research Fellow at BMS, Bristol-Myers Squibb

Enhancing Preclinical Strategies for Developing Cancer Immunotherapies

Humanized Mouse Models for Drug Discovery Research


  • The addition of 3 human cytokines (GM-CSF, IL-3 & Kit Ligand) into the NSG mouse provide for a more robust myeloid compartment after humanization
  • Showcase data on the myeloid engraftment kinetics and also show checkpoint inhibitor efficacy against several PDX tumors

Immunocompetent Somatic Transgenic Tumor Models (iSTTMs) for Preclinical Brain Tumor Research

  • Joshua Breunig Assistant Professor, Board of Governors Regenerative Medicine Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center


  • Addressing the diverse landscape of preclinical myeloma models
  • Developing biomarker panels through screening of novel agents
  • Adopting preclinical xenograft bone marrow models to investigate late stage diseases

Preclinical Immunocompetent Models for Translational Research

  • Leon Hall Senior Scientific Director, Global Oncology, Crown Bioscience


  • Comparison of immunocompetent mouse models for immunotherapy PD/efficacy studies
  • Examples of targeted therapy/immunotherapy combinations and other approaches to condition the tumor microenvironment
  • Overview of the immuno-oncology platform including murine syngeneic screens (MuScreen), GEMM allograft approaches, knock-in mice with chimeric human/mouse targets (HuGEMM), and humanized mouse models

Morning Refreshments & Networking

Elevating Preclinical Outcomes to Identify Effective Combinations with Cancer Immunotherapies

Characterization of Preclinical Mouse Models of Cancer for Effective Targeting of Immune-Suppressive Microenvironment


  • Path to determine which preclinical models are best suited to address anti-tumor effects of immunotherapy combinations
  • Characterization of relative infiltration of immune cell types in commonly used syngeneic tumor models
  • Design of informative pharmacodynamics studies to better understand anti-tumor efficacy of combination immunotherapies

Advanced PDX Tumor Biology Platforms for Drug Advancement

  • Neal Goodwin Vice President Corporate Research Development , Champions Oncology


  • Harnessing large collections of PDX models for more resolute efficacy predictions and the discovery of new therapeutic targets, resistance mechanisms, and biomarker signatures of response
  • How robust systems of myeloid engraftment, including hematopoietic stem cells for immune-oncology modeling and AML engraftment for high throughput multipatient in vivo screens, have now provided expanded PDX screening with a wider scope of therapeutic agents
  • Advancement of coupled-PDX trials, where clinical trials are combined with companion PDX studies to help guide follow-on trial design

Networking Lunch

Preclinical Modeling of Chimeric Antigen Receptor T Cell Therapy and Combination Immunotherapy

  • Saad Kenderian Assistant Professor of Medicine & Oncology, Mayo Clinic


  • To discuss preclinical modeling in CAR-T cell therapy
  • Addressing how preclinical modeling can be used for the evaluation of CAR-T cell toxicities
  • To present strategies for the development of combination immunotherapy

Evaluation of Tumor Models: A Quantitative Analysis

  • Shraddha Sadekar Senior Scientist, Translational PKPD, DMPK & Disposition, Merck


  • Application of tumor modeling in design of preclinical combination studies for immunotherapy
  • How can PK/PD analysis help design in vivo experiments for the development of cancer immunotherapies

Developing Preclinical Models to Predict Clinical Outcomes for Immunotherapy Combination Therapies

  • Andrew Rhim Associate Director for Translational Research, MD Anderson Cancer Center


  • Addressing preclinical and translational challenges to successfully develop novel combinations across therapies
  • What models are advancing preclinical predictions for combination therapies?

Afternoon Refreshments & Poster Session

Tumor Models Interactive Speed Learning – Turning Preclinical Data into Clinical Value


In this interactive session, you will have the opportunity to join the discussion for one of the following topics:

  • Advancing humanized mice- What are the current limitations?

Barbara Joyce-Shaikh, Associate Principal Scientist, Immunoncology, Merck Research Laboratories

  • How can we use preclinical models to optimize the predictability of novel combination therapies?

Angie Park, Senior Director, Immunotherapy & Stem Cell Biology, OncoMed Pharmaceuticals

  • What are the best models to use to develop cell & ex vivo therapies?

Shon Green, Scientist, Preclinical Development, Eureka Therapeutics

Chair’s Closing Remarks

  • Francis Lee Independent Immunopharmacology Consultant - , Formerly Senior Research Fellow at BMS, Bristol-Myers Squibb

Drinks Reception Hosted by The Jackson Laboratory